Immune Checkpoint Inhibitors Convey Survival Benefit in Elderl...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
DENVER, Sept. 14, 2021 /PRNewswire-AsiaNet/ -- Because elderly patients with non-small cell lung cancer are likely to be excluded from clinical trials due to their lower functional capacity or comorbidities, survival benefit from immune checkpoint inhibitors (ICIs) remains unclear. In patients...
Authors: LATEST ASIANET NEWS RELEASES